BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab - Archive ouverte HAL Access content directly
Journal Articles American Journal of Hematology Year : 2017

BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab

(1, 2) , (3) , (4) , (5, 6) , (3) , (3) , (3) , (3) , (7) , (8) , (9) , (10, 11) , (12, 13) , (8, 2) , (2, 1)
1
2
3
4
5
6
7
8
9
10
11
12
13

Abstract

BCL2 mutations have been suggested to confer an adverse prognosis to follicular lymphoma (FL) patients, but their prognostic value has not been assessed in patients treated with a rituximab-containing regimen. Here we evaluated the prognostic value of BCL2 mutations in a large prospective cohort of 252 patients with FL treated with immunochemotherapy in the PRIMA randomized trial. Using a DNA-targeted sequencing approach, we detected amino acid altering mutations in 135 patients (54%) and showed that these mutations were probably mediated by the over-activation of AICDA (activation-induced cytidine deaminase) in the context of the t(14;18) translocation. The BCL2 variants identified in PRIMA patients affected the BH1, BH2, and BH3 functional motifs at a lower frequency than the N-terminus and flexible loop domain, with mostly conservative aminoacid changes. With a median follow-up of 6.7 years, we did not observe any impact of BCL2 mutations either on overall survival or progression-free survival.
Fichier principal
Vignette du fichier
huet2017_2.pdf (1.16 Mo) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

hal-01524901 , version 1 (24-07-2017)

Identifiers

Cite

Sarah Huet, Edith Szafer-Glusman, Bruno Tesson, Luc Xerri, Wayne J. Fairbrother, et al.. BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab. American Journal of Hematology, 2017, 92 (6), pp.515 - 519. ⟨10.1002/ajh.24701⟩. ⟨hal-01524901⟩
212 View
695 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More